Anavex Life Sciences Corp (AVXL)

[falconer66a]

Dollars per share.

...I don't think it would be unreasonable for Anavex after all costs, expenses, taxes ,etc. to have a net income equal to 25% of that amount, or $20 billion.

Well, if Anavex has 72.42 million shares outstanding (owned by shareholders, the current number as best I can find), $20 billion of revenues splits up to $276.16 per share.

I’ll let those more competent in share pricing tell what a share of AVXL might be worth with those metrics.

All of that presumes that only 20 million people will be receiving Anavex therapy. For CNS diseases (Alzheimer’s, Parkinson’s) that may be reasonable. But if blarcamesine (or, later on Anavex 3-71) prove to prophylactically prevent the onset of a host of geriatric debilities (very possible), perhaps a hundred million across the globe each year would benefit from Anavex therapy.